A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.
In patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial.
Chelation therapy to remove potentially toxic levels of lead was not associated with a reduction in CV events in post-MI patients with diabetes in the TACT2 trial.
Modest financial incentives and gamification encouraged people with cardiovascular risks to meaningfully increase daily step counts over 18 months, in the BE ACTIVE trial.